Screening all men for prostate cancer using the PSA blood test has not been shown to be effective, so researchers are trying different techniques to see if they can identify a particular group of men who would benefit from regular testing.
The Memorial Sloan-Kettering Cancer Center has released new research published in the British Medical Journal today (17 April 2013) which explores whether measuring PSA levels in men aged 40-55 could predict their risk of dying from prostate cancer later in life.
Commenting on the study Dr Sarah Cant, Director of Policy and Strategy at Prostate Cancer UK said: "This research takes us a step closer to developing better knowledge about which men could be at higher risk of developing aggressive forms of prostate cancer in later life. But more research must be done to get us closer to a targeted screening programme for this disease which is so desperately needed.
"Ultimately, this study further highlights that there is still a long way to go until understanding of this neglected disease gets where it needs to be. Research into developing a more reliable test for this cancer must be substantially increased if we are to get closer to reducing the number of men dying from the disease in the future."